Stocks · News reference

8-K/A filing — Atrium Therapeutics, Inc. (RNA)

Oct 9, 2026, 10:17 AMSEC EDGAR

Filed: 2026-10-09 AccNo: 0001193125-26-418417 Size: 146 KB Item 8.01: Other Events

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGAROct 8, 2026, 10:52 AMSEC EDGAR
8-K filing — Atrium Therapeutics, Inc. (RNA)
Filed: 2026-10-08 AccNo: 0001193125-26-417402 Size: 685 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
RNA
BenzingaOct 8, 2026, 10:36 AMBenzinga Newsdesk
Atrium Therapeutics Announces $50M Private Placement Of 5,170,384 Shares And Pre-Funded Warrants To Purchase Up To 1,134,930 Shares At ~$7.93/Unit
Company entered into a securities purchase agreement (the "purchase agreement") with a group of leading institutional investors for a private placement financing (the "private placement"). The private
RNA
BenzingaAug 14, 2026, 5:27 PMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Atrium Therapeutics (NASDAQ:RNA) with a Buy and maintains $25 price target.
RNA